# Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease

> **NCT02301936** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 10 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** LDV/SOF

## Key facts

- **NCT ID:** NCT02301936
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-02
- **Primary completion:** 2016-04-18
- **Final completion:** 2016-04-18
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2018-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02301936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02301936, "Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02301936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*